ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 1962

Utility of 18 FDG-PET/CT Scans in the Diagnosis of Polyarteritis Nodosa and Other Medium Vessel Vasculitis

Nouran Eshak1, Kristina Yancey2, Felipe Martinez3, Lester Mertz1, carolyn mead harvey4, Kenneth Warrington5, Matthew Koster5 and Megan Sullivan1, 1Mayo Clinic Arizona, Scottsdale, AZ, 2Mayo Clinic Arizona, Phoenix, AZ, 3Mayo Clinic Arizona, Phoenix, 4Mayo Clinic Florida, Jacksonville, FL, 5Mayo Clinic, Rochester, MN

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Imaging, Polyarteritis nodosa, Vasculitis

Session Information

Date: Monday, November 18, 2024

Title: Imaging of Rheumatic Diseases Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Medium vessel vasculitis (MVV), including polyarteritis nodosa (PAN), presents significant diagnostic challenges with patients frequently exhibiting non-specific systemic manifestations. While 18F-fluorodeoxyglucose PET/CT (PET/CT) is widely used for large vessel vasculitis, its application in MVV is unclear. A previous case series of 10 patients by Fagart et al. has shown that FDG-PET/CT can reveal characteristic abnormalities such as increased tracer uptake in muscle compartments and medium sized vessels. This study evaluates the diagnostic efficacy of PET CT in a cohort of patients with medium vessel vasculitis.

Methods: This retrospective study utilized data from Mayo Clinic’s records. We reviewed 369 charts and identified 45 patients diagnosed with MVV who underwent PET/CT scans for disease evaluation. Patients were categorized into four groups: PAN meeting classification criteria (n=16, 35.6%), clinician-diagnosed PAN (n=15, 33.3%), medium vessel vasculitis not diagnosed as PAN (n=11, 24.4%), and cutaneous PAN (n=3, 6.7%). Descriptive statistics are reported by group, and differences were tested using Kruskal-Wallis and Fisher’s exact tests.  

All PET/CT scans were performed without intravenous contrast. They were considered positive if the vessel wall tracer activity was higher than the blood pool activity regardless of CT findings. Active myositis was defined as increased FDG accumulation higher than normal muscle background activity. 

Results: Of the 45 patients, 27 (60%) were male and 39 (88.6%) were white, with a mean age at diagnosis of 55.8 years. Clinical manifestations included constitutional symptoms in 29 (64.4%), neurologic involvement in 19 (42.2%), and muscle involvement in 21 (46.7%). Biopsies were done in 30 patients and showed evidence of vasculitis in 20 (66.7%). Excluding those with cutaneous PAN, PET/CT scans were positive, i.e., showed evidence of FDG uptake in vessels, in 13 (31%) patients and negative in 27 (64.2%), 2 (4.8%) were non-specific (defined as muscle uptake only).

Common PET/CT findings included uptake in lower extremity vessels (10), muscles (7), and iliac arteries (5). The most common pattern of muscle uptake was linear (6/7). Location of uptake did not differ significantly between disease groups. Glucocorticoid use prior to PET/CT was common and reported in 19 (45.2%). Of those without prior glucocorticoid use 11/23 (47.8%) were positive versus 2/19 (10.5%) with prior use. Prior glucocorticoid use was inversely associated with a positive PET/CT (p=0.017). 

Conclusion: PET/CT scans can show characteristic findings in MVV, with predominant involvement of lower extremity vessels and linear muscle uptake. However, there is limited sensitivity for diagnosing MVV and this can be further influenced by glucocorticoid use, highlighting the need for careful consideration of pre-scan treatment regimens. These findings suggest that PET/CT should be used with other diagnostic modalities for a comprehensive evaluation. 

References:
1Fagart, A. et al. “Fluorodeoxyglucose positron emission tomography–computed tomography findings in a first series of 10 patients with polyarteritis nodosa.” Rheumatology 61.4 (2022): 1663-1668.

Supporting image 1

18-FDG PET/CT scan findings in patients with medium vessel vasculitis

Supporting image 2

Table 1: Clinical Characteristics, Labs, Biopsy and Imaging in patients with Medium Vessel Vasculitis

Supporting image 3

Table 2: 18 FDG-PET/CT Scan Findings among non-cutaneous PAN.


Disclosures: N. Eshak: None; K. Yancey: None; F. Martinez: None; L. Mertz: None; c. mead harvey: None; K. Warrington: Amgen, 2, Bristol-Myers Squibb(BMS), 5, Eli Lilly, 5, sanofi, 2; M. Koster: Amgen, 1; M. Sullivan: None.

To cite this abstract in AMA style:

Eshak N, Yancey K, Martinez F, Mertz L, mead harvey c, Warrington K, Koster M, Sullivan M. Utility of 18 FDG-PET/CT Scans in the Diagnosis of Polyarteritis Nodosa and Other Medium Vessel Vasculitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/utility-of-18-fdg-pet-ct-scans-in-the-diagnosis-of-polyarteritis-nodosa-and-other-medium-vessel-vasculitis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-18-fdg-pet-ct-scans-in-the-diagnosis-of-polyarteritis-nodosa-and-other-medium-vessel-vasculitis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology